SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Helus Pharma Reports Fiscal Q2 Results, Positive Phase 3 Study Data

Helus Pharma reported fiscal second-quarter 2027 results and positive topline results from its Phase 3 APPROACH study of HLP003 as an adjunctive treatment for major depressive disorder.

HELP

Helus Pharma (HELP) shares drew significant investor attention in Monday’s premarket trade after the company reported its fiscal second-quarter 2027 results and announced positive topline results from its Phase 3 APPROACH study evaluating HLP003 as an adjunctive treatment for major depressive disor…

Related stories